Home
About Us
Hycells Profile
Corporate Culture
Honors Qualifications
Contact Us
Sample Service
Immune Cells
Hepatocytes
Stem Cells
Featured Products
Cultivation Products
Testing Products
Other Products And Instruments
Technical Service Platform
Specialized Sample Services
Conventional Drug Efficacy Evaluation
Granulocyte Function Experiment
Whole Blood/Serum Test
Drug Immunogenicity Testing
Drug Blood Toxicity Testing
Technology Center
Frequently Asked Questions
Operational Skills
Training Salon
Blog
Company News
Industry Trends
Laws Regulations
Language
中文版
English
All Categories >
11
2025-08
Cell Feeder bottom-permeable cell culture flasks | High-yield protocol for immune cell expansion, no medium change or replenishment required after 7 days.
Cell culture flasks serve as vessels for cell culture and expansion, offering the advantage of accommodating large cell densities and supporting long-term cultivation. These flasks typically feature a high surface-area-to-volume ratio, which promotes adherent cell growth and efficient nutrient exchange, facilitates subculturing and expansion, and meets the demands of research requiring large cell numbers. However, when using conventional cell culture flasks for cell expansion, frequent manual interventions are necessary to adjust cell density and replenish fresh culture medium, thereby increasing the risk of contamination. In contrast, permeable culture bags or bioreactors represent alternative approaches for large-scale production of CIK, T, and NK cells. Yet, culture bags require substantial volumes of fresh medium and frequent adjustments of cell density, while visual monitoring is inconvenient and relies on sampling or external sensors to assess cell status; bioreactors, on the other hand, are bulky, expensive, and complex to operate. The G-Rex series of culture flasks has been widely validated and adopted by users; however, this series is costly and subject to supply instability.
2025-08-11
07
2025-07
When we stand together, we achieve the extraordinary—A complete record of Hycells Bio’s 2025 mid-year team-building event!
The June sun shines warmly and brightly, prompting the team at Heyou Bio to momentarily set aside their pipettes and culture flasks. Leaving behind the cell culture rooms and laminar flow hoods, they head off to fulfill a promise—a bond between the team and nature. While experimental data demands rigor, team-building activities call for even more excitement!
2025-07-07
An integrated culture protocol for harvesting high-density, high-quality NK cells without the need for medium exchange or supplementation: seed cells + serum-free culture kit + large-capacity expansion culture flasks.
Natural killer (NK) cells are a core component of the innate immune system and represent the most potent and effective immune cells in the fight against cancer cells and viruses. Originating in the bone marrow, they constitute the third major class of lymphocytes, alongside T cells and B cells, accounting for approximately 15% of all immune cells (white blood cells) in the bloodstream. NK cells are predominantly found in peripheral blood, the liver, the spleen, and the placenta.
Hycells New Product | IFN-γ ELISPOT Assay Kit
Enzyme-linked immunospot assay: The term “enzyme-linked” carries the same meaning as in ELISA, referring to an immunoassay that relies on enzymatic reaction amplification. As with ELISA, the antibodies used in ELISPOT are also adsorbed (coated) onto a solid support; the key difference is that in ELISA the antibodies capture target proteins that are already present and uniformly distributed in the sample solution, whereas in ELISPOT the antibodies capture proteins freshly secreted by cells in response to dynamic stimulation.
04
618 Special Offer | 10 Million Sorted CD3+ T Cells for Only ¥618
The moment T cells traverse the vascular endothelium and precisely recognize cancer-specific targets, all the rigorous preclinical screening is truly worthwhile.
2025-07-04
Anti-FMC63 Antibody | Put Your CD19 CAR-T Therapy Ahead from the Start
Since its development in the 1980s, the FMC63 antibody has become a core component of chimeric antigen receptor T-cell (CAR-T) therapy. Its successful application in the treatment of B-cell malignancies marks a significant breakthrough in cancer immunotherapy. CD19 is a transmembrane protein specifically expressed on the surface of B cells, involved in B-cell receptor signaling and playing a critical role in B-cell development and malignant transformation. It is expressed in most B-cell malignancies, including acute lymphoblastic leukemia and diffuse large B-cell lymphoma, making it an ideal therapeutic target.